Overview

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
0
Participant gender:
Female
Summary
The objective of the study is to evaluate the efficacy and safety of chemotherapy plus deferoxamine in metastatic breast cancer whose evaluation is stable disease with a trend of progression.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Deferoxamine
Criteria
Inclusion Criteria:

- Has measurable metastatic triple-negative breast cancer, with at least 1 measurable
lesion per RECIST criteria.

- Fail second-line or above anti-tumor treatment

- Evaluation is stable disease with a trend of progression.

- Minimum life expectancy 16 weeks

- Histological confirmation of breast cancer on primary tumour at diagnosis/on biopsy of
metastasis

- ECOG Performance Status (PS) 0-2 with no deterioration over previous 2 weeks

- Normal organ function.

- Has signed a Patient Informed Consent Form.

Exclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) score of ≥ 2

- Patients with severe liver and kidney insufficiency

- Deferoxamine Ingredients allergy

- With the exception of alopecia, any unresolved toxicities from previous therapy
greater than CTCAE grade 1 before study treatment

- Inability or unwillingness to comply with study procedures, including inability to
take regular oral medication

- Researchers consider it is not suitable for participation.